SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus wins Federal Circuit Appeal in generic version of Lialda (Mesalamine)

10 May 2017 Evaluate

The United States Court of Appeals for the Federal Circuit has affirmed judgment in favour of Zydus Cadila’s US subsidiary, Zydus Pharmaceuticals (USA) Inc., holding that its proposed generic version of Lialda (Mesalamine) does not infringe U.S. Patent No. 6,773,720.

Lialda is indicated for the induction of remission of active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects around 700,000 people in the United States.

Zydus was the first pharmaceutical company to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda (Mesalamine). The Court of Appeals’ decision is a major step toward Zydus providing a generic version of Lialda (Mesalamine) in the United States. Shire has reported annual sales of $714 million for this product in 2016 in the United States.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×